Clinical trial · Interventional
Cholecalciferol in Treating Patients With Myelodysplastic Syndrome
Orthomolecular Vitamin D3 in Low-Risk Myelodysplastic Syndrome: An Open-Label Clinical Trial
NCT00068276CI-TRIAL-00034269completedPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
RATIONALE: Cholecalciferol (vitamin D) may improve quality of life by increasing blood counts, decreasing fatigue, and improving other symptoms of myelodysplastic syndrome. PURPOSE: This phase II trial is studying how well cholecalciferol works in treating patients with myelodysplastic syndrome.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Leukemia | Leukemia | ONTOLOGY_EXACT | 0.90 |
| Myelodysplastic/Myeloproliferative Neoplasms | Myelodysplastic/Myeloproliferative Neoplasm | CURATED_BROADER | 0.80 |
| Myelodysplastic Syndromes | Myelodysplastic Syndrome | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| cholecalciferol | Dietary Supplement | — | UNRESOLVED |
Eligibility
Eligibility (as posted)
- Sex
- All
- Maximum age
- 120 Years
Show eligibility criteria text
DISEASE CHARACTERISTICS: * Histologically confirmed myelodysplastic syndromes (MDS) * Must have undergone bone marrow aspirate and biopsy with karyotype within the past 3 months * International Prognostic Scoring System score of 0 or 1 PATIENT CHARACTERISTICS: Age * Any age Performance status * Any Life expectancy * More than 1 year Hematopoietic * Not specified Hepatic * Not specified Renal * No history of hypercalcemia PRIOR CONCURRENT THERAPY: Biologic therapy * Prior stem cell transplantation allowed * No concurrent hematopoietic growth factors Chemotherapy * Not specified Endocrine therapy * Not specified Radiotherapy * Not specified Surgery * Not specified Other * More than 6 weeks since prior cholecalciferol supplements or analogs * More than 4 weeks since any prior therapy for MDS (except supportive care) * No other concurrent therapy for MDS
References
Publications (0)
Data not yet available
No reference posted for this study.